Tavneos (Avacopan) Patent Expiration, LOE Window & CMS Spending

Tavneos (Avacopan) by Amgen: FDA Orange Book core substance LOE 2039-11-27, 0 AB generics, $101.6M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAmgen
FDA Application & PathwayN214487 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2039-11-27
Last Listed Patent or Exclusivity Date2039-11-27
Orange Book Patents (*PED Extensions)4 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$101.6M
2024 Medicare Part D Spend$76.0M
2024 Medicaid Spend$25.5M
Reported Wholesale Price Change (CA SB 17)4 WAC filings (max 23.8% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Amgen across sibling Meru public-data platforms.